GlassScriptPhysician profile
Renee Koehler
NPI 1235975350
$1,511.64
in general payments reported to CMS, 2019-2025
22 companies · $840 in 2025
The $840 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $671 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $291.52 | 2024-2025 | Farxiga, Fasenra |
| Lilly USA, LLC | $148.54 | 2024-2025 | Zepbound, Mounjaro |
| Lundbeck LLC | $136.73 | 2024-2025 | Brintellix, Rexulti |
| Abbvie INC. | $136.28 | 2024-2025 | |
| Novo Nordisk INC | $123.14 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.16 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $89.34 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $63.68 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corium, LLC | $50.93 | 2024-2025 | Azstarys |
| Axsome Therapeutics, INC. | $50.07 | 2024-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $47.59 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $46.23 | 2025 | Zenpep |
| Shield Therapeutics INC | $39.08 | 2024 | |
| Pfizer INC. | $36.39 | 2024-2025 | |
| Alkermes, INC. | $26.14 | 2025 | Aristada, Lybalvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $23.36 | 2024 | |
| Astellas Pharma US INC | $22.76 | 2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $20.40 | 2025 | Nuzyra |
| Phadia US INC. | $16.39 | 2025 | Immunocap |
| Collegium Pharmaceutical, INC. | $16.14 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $14.92 | 2025 | Relexxii |
| Corcept Therapeutics | $14.85 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Koehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.